Two biotechs have now cleared the threshold separating longevity science from regulated medicine. This week’s $435 million raise by NewLimit is the latest signal that epigenetic reprogramming is no longer a fringe idea.

For most of its short history, the field of longevity medicine has attracted as many sceptics as supporters. The promises have tended to outrun the evidence, and a crowded landscape of unregulated peptide clinics, biohacking influencers and speculative supplements has done little to help the scientific credibility of serious researchers working in the same broad space. That is beginning to change. In 2026, the science of cellular reprogramming has crossed a threshold that separates academic biology from regulated drug development, and the financial markets have noticed.

On 2 June, NewLimit, a South San Francisco-based biotechnology company, announced it had raised $435 million in a Series C round led by Founders Fund, tripling its valuation to approximately $3.1 billion in roughly twelve months. The company plans to use the capital to advance its lead programme, a prototype medicine designed to reverse cell age in old human liver cells, into first-in-human clinical trials next year. The accelerated timeline, the company said, was driven by a laboratory breakthrough that produced results far more compelling than the team had expected at that stage of development.

It is a striking moment for a field that many mainstream scientists once kept at arm’s length.

What Epigenetic Reprogramming Actually Means

To understand why this matters, it helps to understand what the science is actually attempting to do. Ageing is not simply the accumulation of damage over time. It is also driven by changes to the epigenome: the collection of chemical marks that sit on top of DNA and control which genes are switched on or off in each cell. As cells age, these marks shift in ways that cause cells to lose their specialised functions and become more susceptible to disease.

The foundational insight came in 2006, when Japanese scientist Shinya Yamanaka demonstrated that mature, differentiated cells could be reprogrammed back to a stem-cell-like state by introducing four specific transcription factors, now known as the Yamanaka factors. Working with OCT4, SOX2, KLF4 and c-MYC, collectively abbreviated as OSKM, Yamanaka demonstrated that differentiated adult cells could be reprogrammed back to a pluripotent state resembling embryonic stem cells. He received the Nobel Prize in Physiology or Medicine for this work in 2012.

The problem with full reprogramming is that it strips cells of their identity entirely, raising serious risks including tumour formation. The approach that companies like NewLimit and Life Biosciences are pursuing is different: partial reprogramming, in which cells are exposed to reprogramming factors for long enough to reverse epigenetic ageing but not long enough to lose their specialised function. Partial reprogramming fits neatly into the concept that ageing is driven not only by the accumulation of damage over time, but also by changes to a cell’s epigenome, and Yamanaka factors interact with the epigenetic machinery of a cell to rewind some of these changes.

The question that has consumed researchers for years is whether this can be done safely and reproducibly in humans.

Two Companies, Two Targets

NewLimit is not alone in attempting to answer that question. Life Biosciences, a Boston-based company built on research from Harvard professor David Sinclair, moved first. In January 2026, the FDA cleared Life Biosciences’ Investigational New Drug application for ER-100, marking the first ever cellular rejuvenation therapy using partial epigenetic reprogramming to reach human clinical trials. The Phase 1 study is enrolling patients with open-angle glaucoma and non-arteritic anterior ischaemic optic neuropathy, conditions characterised by the irreversible death of retinal cells that connect the eye to the brain. The trial is primarily assessing safety and tolerability, as is standard for a first-in-human study.

The eye is a logical first target. It is a contained anatomical site, immune-privileged in ways that reduce the risk of systemic inflammatory reactions, and has well-established outcome measures for visual function. It is also a tissue in which Sinclair’s team had previously demonstrated restoration of function in animal models, including non-human primates, giving the programme a stronger preclinical foundation than most.

NewLimit is targeting the liver. The company has identified prototype medicines spanning three therapeutic areas, including liver reprogramming via transcription factor combinations that restore aged liver cells’ ability to process fat and alcohol, showing effectiveness in animal models of liver disease, as well as immune system rejuvenation and a vascular programme targeting the endothelial cells that line blood vessels. Its lead programme uses lipid nanoparticle-delivered RNA medicines to transiently express combinations of transcription factors in aged hepatocytes, a delivery mechanism that is already well understood from the mRNA vaccine platform.

CEO Jacob Kimmel, a stem cell biologist by training, was candid in noting that whilst longevity is one of the hottest areas in biotech today, the field has also been rife with charlatans and hucksters, with historically a lot of over-salesmanship and a lack of rigorous science in ageing biology. That acknowledgement of the field’s credibility problem is itself a mark of seriousness.

The Investment Landscape

The scale of capital now flowing into this space reflects a broader shift in how institutional investors are thinking about longevity. Eli Lilly Ventures’ continued participation in NewLimit is notable, given Lilly’s expanding interest in metabolic and age-related biology following the commercial success of its GLP-1 franchise. The involvement of a major pharmaceutical company’s venture arm, alongside Founders Fund, Thrive Capital and Kleiner Perkins, signals that this is no longer purely a Silicon Valley moonshot.

Altos Labs, the $3 billion cellular rejuvenation company backed by Jeff Bezos and other technology investors, has also been signalling a shift towards clinical development, appointing an experienced clinical medicine specialist as chief medical officer in 2025. The trajectory across the sector points in the same direction: from foundational biology towards regulated trials.

The Regulatory and Scientific Challenges That Remain

None of this should be mistaken for a solved problem. The science is genuinely promising. The risks are also genuine. Full reprogramming carries the risk of inducing tumour formation; partial reprogramming has shown a far better safety profile in preclinical models, but long-term data in humans do not yet exist. Dosing, timing, delivery and tissue specificity are all variables that remain to be worked out in clinical settings.

There is also a regulatory complication that sits beneath the surface of all of this. The FDA does not currently recognise ageing itself as a disease, which means these trials are proceeding under existing frameworks targeting specific age-related conditions rather than ageing as a primary indication. That creates an approval pathway, but it also shapes what questions the trials are designed to answer. A therapy that reverses cellular age in liver cells may still need to demonstrate clinical benefit in a specific and measurable condition to achieve regulatory approval.

What the next two years will bring is the first human safety and efficacy data on partial epigenetic reprogramming from multiple programmes simultaneously. Life Biosciences’ eye trial and NewLimit’s planned liver trial will not resolve every question, but they will generate the kind of evidence that either validates the platform or forces it to be redesigned.

For a field that has spent years promising more than it could prove, that moment of reckoning is both long overdue and genuinely significant. The biology is compelling. The capital is committed. The trials are beginning. Whether epigenetic reprogramming ultimately delivers medicines that meaningfully extend healthy human life will be determined not by the fundraising announcements, but by what happens next in the clinic.

Sources include NewLimit, Life Biosciences, Fierce Biotech, STAT News, BioSpace, Scientific American, Lifespan.io and the FDA.